TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27547421

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily
Number of subjects: 78

Group type: COMPARATOR
Intervention: Voglibose 0.2 mg three times a day
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 78
Study: 24418801

Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (LLLT) applied at five acupuncture points on the affected knee during nine sessions.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo low-level laser therapy (LLLT) applied at five acupuncture points on the affected knee during nine sessions.
Number of subjects: 49
Study: 22079773

Group type: EXPERIMENTAL
Intervention: 75 mg XR‐NTX
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 150 mg XR‐NTX
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 300 mg XR‐NTX
Number of subjects: 27
Study: 19330703

Group type: EXPERIMENTAL
Intervention: 3 hourly feeds
Number of subjects: 92

Group type: COMPARATOR
Intervention: 2 hourly feeds
Number of subjects: 92
Study: 17595249

Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg/d
Number of subjects: 56

Group type: COMPARATOR
Intervention: diet alone
Number of subjects: 56
Study: 15346755

Group type: EXPERIMENTAL
Intervention: Transmandibular implant
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Augmentation of the mandible with an autologous bone graft followed by placement of 4 endosseous implants
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placement of 4 endosseous implants only
Number of subjects: 60
Study: 11224756

Group type: COMPARATOR
Intervention: Iomeprol
Number of subjects: 3200

Group type: EXPERIMENTAL
Intervention: Iomeprol-containing liposomal formulations
Number of subjects: 3200
Study: 9586887

Group type: EXPERIMENTAL
Intervention: Dacarbazine plus interferon (IFN)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Dacarbazine without interferon (IFN)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Dacarbazine plus tamoxifen (TMX)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Dacarbazine without tamoxifen (TMX)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Treatments containing interferon (IFN)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Treatments without interferon (IFN)
Number of subjects: 271
Study: 7733596

Group type: EXPERIMENTAL
Intervention: Totally pre‐peritoneal video‐surgery
Number of subjects: 181

Group type: COMPARATOR
Intervention: Classic Shouldice herniography
Number of subjects: 181
Study: 2719175

Group type: EXPERIMENTAL
Intervention: Histamine chloride control (10 mg/ml)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Buffered glycerol-saline diluent control
Number of subjects: 484
Study: 31481307

Group type: EXPERIMENTAL
Intervention: Unprotected LMS
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: STEMI PCI in unprotected LMS
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Independent predictors of in-hospital death and major adverse cardiovascular events
Number of subjects: 469
Study: 30536639

Group type: EXPERIMENTAL
Intervention: Bounding Exercise Program (BEP)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (regular training program)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both groups (BEP and Control)
Number of subjects: 400
Study: 27548732

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Hypocaloric diet (HCD)
Number of subjects: 75
Study: 24746974

Group type: EXPERIMENTAL
Intervention: Lupin protein (LP) 25 g/d
Number of subjects: 72

Group type: COMPARATOR
Intervention: Milk protein plus arginine (MPA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Milk protein (MP)
Number of subjects: 72
Study: 24798861

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) training for 8 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 110
Study: 23054692

Group type: EXPERIMENTAL
Intervention: 50 mg empagliflozin q.d. for 5 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coadministration of 50 mg empagliflozin q.d. and 100 mg sitagliptin q.d. over 5 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: 100 mg sitagliptin q.d. for 5 days
Number of subjects: 16
Study: 19541737

Group type: EXPERIMENTAL
Intervention: Mental stress (via mental arithmetic)
Number of subjects: 16

Group type: COMPARATOR
Intervention: HDT
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined mental stress and HDT
Number of subjects: 16
Study: 17448065

Group type: EXPERIMENTAL
Intervention: Levitan FPS scope (LFPS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Single-use bougie
Number of subjects: 34
Study: 15601268

Group type: EXPERIMENTAL
Intervention: Remifentanil 40 microg with a 2‐min lockout
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pethidine 15 mg with a 10‐min lockout
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 39
Study: 12584829

Group type: EXPERIMENTAL
Intervention: Yishenkang granule (YSKG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sanjin tablet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 120
Study: 10506687

Group type: EXPERIMENTAL
Intervention: Ocular spray administration
Number of subjects: 126

Group type: COMPARATOR
Intervention: Ocular drops administration
Number of subjects: 126
Study: 7503039

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) with a 30 mW gallium-arsenide-aluminium (830 nm) diode laser probe for 15, 30, and 60 seconds.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo treatment for 30 seconds.
Number of subjects: 39
Study: 2020093

Group type: EXPERIMENTAL
Intervention: Midazolam 4 mg i.m. (Group M)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hydroxyzine 50 mg i.m. (Group H)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg and pentazocine 6 mg for intraoperative sedation (both groups)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Midazolam and pentazocine maintenance doses (both groups)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Midazolam (Group M)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hydroxyzine (Group H)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 6121709

Group type: EXPERIMENTAL
Intervention: Somatostatin (1 microgram kg‐1h‐1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Somatostatin (2 microgram kg‐1h‐1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Indomethacin alone
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Somatostatin with prior indomethacin administration
Number of subjects: 5
Study: 29727331

Group type: EXPERIMENTAL
Intervention: ALPPS (Associating Liver Partition and Portal vein ligation for Staged hepatectomy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALPPS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional 2-stage hepatectomy including portal vein embolization
Number of subjects: 0
Study: 27544017

Group type: EXPERIMENTAL
Intervention: we DECide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25791145

Group type: EXPERIMENTAL
Intervention: Duloxetine (30‐120 mg daily)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 23397566

Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated catheters (Bactiseal(®))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Silver-bearing catheters (VentriGuard(®))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study: 21808398

Group type: EXPERIMENTAL
Intervention: Video laryngoscopy (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional laryngoscopy (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 30
Study: 19912626

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: BI
Number of subjects: 246
Study: 17159373

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBO) - Group A: 2.2 bar for 60 min bottom time
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBO) - Group B: 2.5 bar for 60 min bottom time
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Patients with positive expectation of HBO effects
Number of subjects: 360

Group type: COMPARATOR
Intervention: Patients with indifferent expectation of HBO effects
Number of subjects: 360

Group type: COMPARATOR
Intervention: Patients with negative expectation of HBO effects
Number of subjects: 360
Study: 15602194

Group type: EXPERIMENTAL
Intervention: RIX4414 live attenuated human rotavirus vaccine
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 11529281

Group type: EXPERIMENTAL
Intervention: omalizumab every 2 or 4 weeks subcutaneously for 7 months
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: omalizumab during the steroid-reduction phase
Number of subjects: 546

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 546
Study: 9753250

Group type: EXPERIMENTAL
Intervention: rebamipide 100 mg thrice daily for eight weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: teprenone 50 mg thrice daily for eight weeks
Number of subjects: 102
Study: 7877584

Group type: EXPERIMENTAL
Intervention: SST+MLD (standard surgical treatment plus medicinal lymph node dissection)
Number of subjects: 172

Group type: COMPARATOR
Intervention: SST only (standard surgical treatment)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: SST+MLD
Number of subjects: 172
Study: 2899718

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Urokinase
Number of subjects: 45
Study: 31684757

Group type: EXPERIMENTAL
Intervention: Screen time usage (various types)
Number of subjects: 0
Study: 30272428

Group type: EXPERIMENTAL
Intervention: Long-term rent subsidies
Number of subjects: 2282

Group type: EXPERIMENTAL
Intervention: Short-term rent subsidies
Number of subjects: 2282

Group type: EXPERIMENTAL
Intervention: Transitional housing with intensive psychosocial services
Number of subjects: 2282

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2282
Study: 27864462

Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IAT)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IAT) for grade 3 collateral status
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IAT) for grade 2 collateral status
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IAT) for grade 1 collateral status
Number of subjects: 449

Group type: COMPARATOR
Intervention: Standard care (control) for grade 0 collateral status
Number of subjects: 449
Study: 26334726

Group type: EXPERIMENTAL
Intervention: Fixed-dose intravenous combination of 3 mg/mL ibuprofen and 10 mg/mL paracetamol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral formulation of the same doses of ibuprofen and paracetamol
Number of subjects: 30
Study: 24014734

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (1000 IU/day)
Number of subjects: 2259
Study: 21740249

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 491

Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 491
Study: 19861516

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 2166

Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 2166
Study: 16611155

Group type: EXPERIMENTAL
Intervention: Pharmacological agents to prevent aneurysm expansion and rupture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 15475664

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 145
Study: 11733267

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Posterior episcleral buckle procedure (PEBP)
Number of subjects: 30
Study: 9812477

Group type: EXPERIMENTAL
Intervention: Salmonella typhi Vi capsular polysaccharide vaccine (Vi)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Diluted solution (DS) of Vi (placebo)
Number of subjects: 777
Study: 7898090

Group type: EXPERIMENTAL
Intervention: Cilazapril 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilazapril (1.25, 3.75, 10, and 30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilazapril and Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study: 2606883

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31773444

Group type: EXPERIMENTAL
Intervention: Decrease in days of unhealthy drinking
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Increase in days of unhealthy drinking
Number of subjects: 566
Study: 31241192

Group type: EXPERIMENTAL
Intervention: Mobile application-assisted nurse-led management model
Number of subjects: 152

Group type: COMPARATOR
Intervention: Nurse-led asthma management and routine treatment measures (including inhaled corticosteroids)
Number of subjects: 152
Study: 28346869

Group type: EXPERIMENTAL
Intervention: Complex tone with an 8% mistuned harmonic paired with visual displays of one or two bouncing balls
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-tune complex tone paired with visual displays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mistuned harmonic complex paired with visual displays
Number of subjects: 0
Study: 24733191

Group type: COMPARATOR
Intervention: MTX 12.5 mg once a week
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: TwHF 20 mg three times a day
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: MTX+TwHF combination
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: TwHF
Number of subjects: 207

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 207
Study: 23141837

Group type: COMPARATOR
Intervention: Budesonide 800μg/day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Budesonide 1600μg/day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Budesonide 400μg/day plus montelukast 10μg/day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Budesonide 400μg/day plus carbamylated allergoid of betulaceae
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Budesonide 400μg/day plus immunotherapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (Budesonide 800μg/day)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: All groups except budesonide 800μg/day
Number of subjects: 84
Study: 21705894

Group type: EXPERIMENTAL
Intervention: Daily evaluation and spontaneous breathing test with 10 cm H2O pressure support and 5 cm H2O positive end-expiratory pressure for 2 hours
Number of subjects: 294

Group type: COMPARATOR
Intervention: Standard care procedures for weaning
Number of subjects: 294
Study: 18206846

Group type: EXPERIMENTAL
Intervention: Fixed sequence of action effects with randomly varying transformation rules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed sequence of transformation rules with randomly varying action effects
Number of subjects: 0
Study: 16393445

Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once daily
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study: 14744173

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Nondirective Supportive Therapy (NST)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Lifetime history of sexual abuse
Number of subjects: 107
Study: 10993619

Group type: EXPERIMENTAL
Intervention: Abrupt cessation of TPN
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tapered protocol of TPN
Number of subjects: 21
Study: 9132506

Group type: EXPERIMENTAL
Intervention: Endogenous opioid blockade with naltrexone
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 58
Study: 1621026

Group type: EXPERIMENTAL
Intervention: Biperiden 4 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (Biperiden and Placebo)
Number of subjects: 16
Study: 6359996

Group type: EXPERIMENTAL
Intervention: Detection of Aspergillus fumigatus carbohydrate by radioimmunoassay
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Antibody detection by enzyme‐linked immunosorbent assay
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Diagnostic microbiologic and histopathologic procedures
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prospective nasal cultures
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Radioimmunoassay for A. fumigatus antigen
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Antigenemia detection in second trial
Number of subjects: 39
Study: 30624600

Group type: EXPERIMENTAL
Intervention: Nutrition (Lipid-based nutrient supplements and infant and young child feeding counseling)
Number of subjects: 2169

Group type: EXPERIMENTAL
Intervention: Water, sanitation, and handwashing (WSH)
Number of subjects: 2169

Group type: COMPARATOR
Intervention: WSH+N
Number of subjects: 2169

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2169
Study: 30046691

Group type: EXPERIMENTAL
Intervention: Idarucizumab (1, 2, 4, or 8 g)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Idarucizumab (1, 2, 4, or 5 g) with dabigatran (220 mg bid)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 80
Study: 25895688

Group type: EXPERIMENTAL
Intervention: Minilaparoscopic technique (MLC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard multiport access (CLMP)
Number of subjects: 40
Study: 24374517

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 4705

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 4705
Study: 22813840

Group type: EXPERIMENTAL
Intervention: Paroxetine plus aripiprazole
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sertraline plus aripiprazole
Number of subjects: 24
Study: 19318984

Group type: EXPERIMENTAL
Intervention: Atorvastatin (in amlodipine-based therapy)
Number of subjects: 10305

Group type: EXPERIMENTAL
Intervention: Atorvastatin (in atenolol-based therapy)
Number of subjects: 10305
Study: 17728418

Group type: EXPERIMENTAL
Intervention: Intensive psychosocial intervention (30 sessions over 9 months of interpersonal and social rhythm therapy, cognitive behavior therapy [CBT], or family‐focused therapy)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Collaborative care (a 3‐session psychoeducational treatment)
Number of subjects: 152
Study: 15637976

Group type: EXPERIMENTAL
Intervention: Integrated power toothbrush/toothpaste dispensing system (IntelliClean System from Sonicare and Crest)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Manual toothbrushing coupled with daily flossing (positive control)
Number of subjects: 66
Study: 11431729

Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg bolus plus 0.05 mg/kg.min for 120 minutes)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (the vehicle)
Number of subjects: 7
Study: 9736100

Group type: EXPERIMENTAL
Intervention: Rehabilitative and medically oriented day hospital care
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (home care treatment)
Number of subjects: 177
Study: 8303937

Group type: EXPERIMENTAL
Intervention: LPF toxoid (25 micrograms)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: LPF/FHA (25 micrograms each)
Number of subjects: 75

Group type: COMPARATOR
Intervention: DTP whole‐cell pertussis vaccine
Number of subjects: 75
Study: 2659874

Group type: EXPERIMENTAL
Intervention: 10 mg finoptin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 10 mg fosfobion
Number of subjects: 44
Study: 30499926

Group type: EXPERIMENTAL
Intervention: Express
Number of subjects: 113

Group type: COMPARATOR
Intervention: I‐InTERACT
Number of subjects: 113

Group type: COMPARATOR
Intervention: IRC
Number of subjects: 113
Study: 28482839

Group type: EXPERIMENTAL
Intervention: Alkanna tinctoria extract ointment (20%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dressing (control)
Number of subjects: 0
Study: 25608876

Group type: EXPERIMENTAL
Intervention: Geriatric Care Model
Number of subjects: 35
Study: 22837547

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention delivered by dental hygienists; duration: 3-5 minutes; includes motivational interviewing and personalized normative feedback.
Number of subjects: 0
Study: 21770995

Group type: EXPERIMENTAL
Intervention: Air-abrasive device (AAD) with amino acid glycine powder
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mechanical debridement (MDA) using carbon curets and antiseptic therapy with chlorhexidine digluconate
Number of subjects: 30
Study: 19309347

Group type: EXPERIMENTAL
Intervention: Topical methyl aminolevulinate (MAL) photodynamic therapy (PDT)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo PDT
Number of subjects: 131
Study: 16679086

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DESs)
Number of subjects: 741

Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 741
Study: 12580662

Group type: EXPERIMENTAL
Intervention: Short-term isokinetic training (2 days of velocity-specific training)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 3
Study: 10736979

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 9366665

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide hydrochloride
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide hydrochloride and 0.5% timolol maleate together
Number of subjects: 40